Our previous work found that the FDA-approved drug tadalafil could act as a novel PRMT5 inhibitor and suppress tumor growth in breast cancer; we aimed to verify whether tadalafil could be used in colorectal cancer treatment. Here, PRMT5 is linked to neoplasm.